• [Hankyung BIO Insight] EOFlow plans to discover and develop various non-insulin drugs to expand on its wearable drug delivery business

    Jul.12.2021
  • EOFlow's establisiment of a wearable pharmaceutical subsidiary 'Pharmeo' to expand on its wearable drug delivery business was introduced on Hankyung BIO Insight on 07/12/2021 (in Korean only): https://www.hankyung.com/it/article/2021071123361

    In summary, reporter Ju-Hyun Lee from Bio & Healthcare department in the Korea Economic Daily announced that EOFlow plans to discover and develop various non-insulin drugs to expand on its wearable drug delivery business through its newly established subsidiary 'Pharmeo Inc'.

    The reporter mentioned that EOFlow sees opportunities in creating new businesses combining drug and EOFlow’s digital wearable drug delivery platform. A wide range of subcutaneously administered drugs with no IP rights exist in areas such as pain management, anti-cancer, and chronic diseases management along with the new biologic drug development is the company's drug candidates. To be more specific, new biologic drugs often suffer from short half-lives which may keep them from commercialization. Combining such new candidates with EOFlow's wearable drug delivery platform allowing several days of continuous infusion may allow or greatly speed up the timing of commercialization. 

     

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here

PRIVACY POLICY